According to the US National Institute of Allergy and Infectious Diseases (NIAID), <a href="https://www.wionews.com/world/no-risk-of-blood-clots-vaccine-100-effective-against-severe-coronavirus-astrazeneca-372252">AstraZeneca</a><a href="https://www.wionews.com/world/no-risk-of-blood-clots-vaccine-100-effective-against-severe-coronavirus-astrazeneca-372252"> </a>may have provided an incomplete view of efficacy data for&nbsp;its COVID-19 vaccine from its trial in the United States.

Watch:

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/no-pork-in-our-vaccine-clarifies-astrazeneca-as-indonesia-raises-concern-372168/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," NIAID said in a statement.&nbsp;

NIAID is headed by US infectious diseases expert Anthony Fauci and is part of the National Institutes of Health with the AstraZeneca vaccine under scanner by health officials.

The vaccine developed by Oxford University is 80 per cent effective against the virus among the elderly, and poses no blood clot risks, the company had said on Tuesday.

German Chancellor Angela Merkel while announcing a five-day lockdown in the country had said she backed the EU Commission President Ursula von der Leyen's decision to ban AstraZeneca vaccines produced in the bloc from being exported unless it delivers more of the 90 million doses it agreed to supply in the first quarter of 2021.&nbsp;

"I support Commission President Ursula von der Leyen," Merkel said, adding, "We have a problem with <a href="https://www.wionews.com/world/astrazeneca-clarifies-its-vaccine-has-no-pork-derived-ingredients-372044">AstraZeneca</a>."

However, according to British pollsters YouGov, a majority of people in the biggest EU states view the AstraZeneca vaccine as unsafe.

According to the US National Institute of Allergy and Infectious Diseases (NIAID), AstraZeneca may have provided an incomplete view of efficacy data for its COVID-19 vaccine from its trial in the United States.

According to the US National Institute of Allergy and Infectious Diseases (NIAID), AstraZeneca may have provided an incomplete view of efficacy data for its COVID-19 vaccine from its trial in the United States. Watch: "The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," NIAID said in a statement. NIAID is headed by US infectious diseases expert Anthony Fauci and is part of the National Institutes of Health with the AstraZeneca vaccine under scanner by health officials. The vaccine developed by Oxford University is 80 per cent effective against the virus among the elderly, and poses no blood clot risks, the company had said on Tuesday. German Chancellor Angela Merkel while announcing a five-day lockdown in the country had said she backed the EU Commission President Ursula von der Leyen's decision to ban AstraZeneca vaccines produced in the bloc from being exported unless it delivers more of the 90 million doses it agreed to supply in the first quarter of 2021. "I support Commission President Ursula von der Leyen," Merkel said, adding, "We have a problem with AstraZeneca." However, according to British pollsters YouGov, a majority of people in the biggest EU states view the AstraZeneca vaccine as unsafe.

AstraZeneca may have included 'outdated' data in vaccine trials: US regulator

Serum Institute of India (SII), the world's biggest vaccine maker by volume, on Sunday asked for patience from foreign governments awaiting their supply of COVID-19 shots, saying it had been directed to prioritise India's requirements.

"...I humbly request you to please be patient," SII's Chief Executive Adar Poonawalla said in a tweet, adding the company "has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world."

"We are trying our best," Poonawalla said.

Based in the western Indian city of Pune, the company is manufacturing the Oxford University/AstraZeneca COVID-19 vaccine, one of the two shots that India is using to initially vaccinate some 300 million people as part of a national inoculation drive.

Many low-and middle-income countries, ranging from Bangladesh to Brazil, are depending on SII's AstraZeneca vaccine, branded COVISHIELD by the Indian company.

But demand is growing, including from Western countries like Canada, where Poonawalla has promised to deliver the COVISHIELD vaccine next month.

Britain's drug regulator is also auditing manufacturing processes at SII, potentially paving the way for the COVISHIELD vaccine to be shipped from there to the UK and other countries..

Indian Prime Minister Narendra Modi's government has come under criticism for the slow take-off of its vaccination drive but health authorities are preparing to expand the number of inoculation substantially in coming weeks.

India has vaccinated around 11 million people since mid-January.

With more than 10.9 million confirmed infections, India has the world's second highest number of COVID-19 cases, behind only the United States.

The country is currently reporting around 12,000 new infections on average each day, a fraction of its peak from last September, according to a Reuters analysis.

But federal health authorities on Sunday said they had written to some states that are currently seeing a surge in cases, asking them to improve overall testing, surveillance and monitoring of COVID-19 mutations.

Serum Institute of India (SII), the world's biggest vaccine maker by volume, on Sunday asked for patience from foreign governments awaiting their supply of COVID-19 shots, saying it had been directed to prioritise India's requirements.

Serum Institute of India (SII), the world's biggest vaccine maker by volume, on Sunday asked for patience from foreign governments awaiting their supply of COVID-19 shots, saying it had been directed to prioritise India's requirements. "...I humbly request you to please be patient," SII's Chief Executive Adar Poonawalla said in a tweet, adding the company "has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world." "We are trying our best," Poonawalla said. Based in the western Indian city of Pune, the company is manufacturing the Oxford University/AstraZeneca COVID-19 vaccine, one of the two shots that India is using to initially vaccinate some 300 million people as part of a national inoculation drive. Many low-and middle-income countries, ranging from Bangladesh to Brazil, are depending on SII's AstraZeneca vaccine, branded COVISHIELD by the Indian company. But demand is growing, including from Western countries like Canada, where Poonawalla has promised to deliver the COVISHIELD vaccine next month. Britain's drug regulator is also auditing manufacturing processes at SII, potentially paving the way for the COVISHIELD vaccine to be shipped from there to the UK and other countries.. Indian Prime Minister Narendra Modi's government has come under criticism for the slow take-off of its vaccination drive but health authorities are preparing to expand the number of inoculation substantially in coming weeks. India has vaccinated around 11 million people since mid-January. With more than 10.9 million confirmed infections, India has the world's second highest number of COVID-19 cases, behind only the United States. The country is currently reporting around 12,000 new infections on average each day, a fraction of its peak from last September, according to a Reuters analysis. But federal health authorities on Sunday said they had written to some states that are currently seeing a surge in cases, asking them to improve overall testing, surveillance and monitoring of COVID-19 mutations.

India's Serum Institute says prioritising domestic vaccine needs, asks for patience

oxford-universityastrazeneca-covid-19-vaccine

Oxford University/astrazeneca Covid 19 Vaccine, News on Oxford University/astrazeneca Covid 19 Vaccine, stories on Oxford University/astrazeneca Covid 19 Vaccine, articles on Oxford University/astrazeneca Covid 19 Vaccine, Oxford University/astrazeneca Covid 19 Vaccine stories at Wion, Oxford University/astrazeneca Covid 19 Vaccine news, Oxford University/astrazeneca Covid 19 Vaccine latest news

oxford universityastrazeneca-covid-19-vaccine

AstraZeneca may have included 'outdated' data in vaccine trials: US regulator

India's Serum Institute says prioritising domestic vaccine needs, asks for patience